807 related articles for article (PubMed ID: 21521865)
21. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
22. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
23. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
24. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
25. Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis.
Durham SH; Garza KB; Eiland LS
Am J Health Syst Pharm; 2016 Jul; 73(13):969-74. PubMed ID: 27325878
[TBL] [Abstract][Full Text] [Related]
26. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
27. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
Horey A; Mergenhagen KA; Mattappallil A
Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
[TBL] [Abstract][Full Text] [Related]
28. Empirical Vancomycin Dosing in Pediatric Patients with Congenital Heart Disease and the Impact of Cardiopulmonary Bypass on Trough Concentrations.
Thomas CA; Picone A; Menon S; Willis BC
Pharmacotherapy; 2017 Nov; 37(11):1341-1346. PubMed ID: 28833385
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacologic clinical monitoring of serum vancomycin levels in pediatric patients].
Nandí-Lozano E; Ramírez-López E; Avila-Figueroa C
Rev Invest Clin; 2003; 55(3):276-80. PubMed ID: 14515672
[TBL] [Abstract][Full Text] [Related]
30. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
Matson KL; Shaffer CL; Beck GL; Simonsen KA
Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
[TBL] [Abstract][Full Text] [Related]
31. Implications of serum creatinine measurements on GFR estimation and vancomycin dosing in children.
Neuman G; Nulman I; Adeli K; Koren G; Colantonio DA; Helldén A
J Clin Pharmacol; 2014 Jul; 54(7):785-91. PubMed ID: 24596064
[TBL] [Abstract][Full Text] [Related]
32. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
Brown DL; Lalla CD; Masselink AJ
Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic monitoring of intravenous vancomycin in a pediatric critical care unit].
Villena R; González CA; Nalegach ME; Vásquez A; Villareal M; Drago M
Rev Chilena Infectol; 2014 Jun; 31(3):249-53. PubMed ID: 25146197
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin prescription in neonates and young infants: toward a simplified dosage.
Oudin C; Vialet R; Boulamery A; Martin C; Simon N
Arch Dis Child Fetal Neonatal Ed; 2011 Sep; 96(5):F365-70. PubMed ID: 21378399
[TBL] [Abstract][Full Text] [Related]
35. A retrospective drug utilization evaluation of vancomycin usage in paediatric patients.
Hing WC; Bek SJ; Lin RT; Li SC
J Clin Pharm Ther; 2004 Aug; 29(4):359-65. PubMed ID: 15271103
[TBL] [Abstract][Full Text] [Related]
36. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
[TBL] [Abstract][Full Text] [Related]
37. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
Inparajah M; Wong C; Sibbald C; Boodhan S; Atenafu EG; Naqvi A; Dupuis LL
Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
[TBL] [Abstract][Full Text] [Related]
38. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of serum vancomycin concentrations in pediatric patients with normal renal function.
Khotaei GT; Jam S; SeyedAlinaghi S; Motamed F; Nejat F; Taghi M; Ashtiani H; Izadyar M
Acta Med Iran; 2010; 48(2):91-4. PubMed ID: 21133000
[TBL] [Abstract][Full Text] [Related]
40. Exploration of once-daily dosing of aminoglycosides through Bayesian simulation.
Garrelts JC
Pharmacotherapy; 1996; 16(2):286-94. PubMed ID: 8820474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
